Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Interest & Investment Income (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Interest & Investment Income for 10 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income rose 2445.21% year-over-year to $1.7 million, compared with a TTM value of $6.9 million through Dec 2025, up 219.36%, and an annual FY2025 reading of $6.9 million, up 219.36% over the prior year.
  • Interest & Investment Income was $1.7 million for Q4 2025 at Zevra Therapeutics, down from $2.3 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $2.4 million in Q2 2025 and bottomed at -$73000.0 in Q4 2024.
  • Average Interest & Investment Income over 5 years is $807100.0, with a median of $628000.0 recorded in 2022.
  • The sharpest move saw Interest & Investment Income skyrocketed 4166.67% in 2022, then crashed 134.76% in 2024.
  • Year by year, Interest & Investment Income stood at $125000.0 in 2021, then skyrocketed by 724.8% to $1.0 million in 2022, then tumbled by 79.63% to $210000.0 in 2023, then plummeted by 134.76% to -$73000.0 in 2024, then soared by 2445.21% to $1.7 million in 2025.
  • Business Quant data shows Interest & Investment Income for ZVRA at $1.7 million in Q4 2025, $2.3 million in Q3 2025, and $2.4 million in Q2 2025.